Literature DB >> 8362719

Spectrum and outcome of congestive heart failure in a hospitalized population.

B Andersson1, F Waagstein.   

Abstract

There are very few contemporary studies on the frequency and cause of congestive heart failure (CHF) in a general population. In western Sweden, inhabited by 1.64 million people, a retrospective survey was performed. All hospital records of patients with CHF, ages 16 through 65 years, were examined in all hospitals in the region. During the study period 2711 patients fulfilled the criteria for CHF or cardiomyopathy. Patients were monitored for 37 +/- 28 months. The most common cause of heart failure was coronary artery disease (IHD) (40%). Other common causes were hypertension (17%), valvular disease (13%), alcohol (11%), diabetes mellitus (10%), and systemic diseases (10%). There were positive correlations between the male sex and IHD, alcohol, and dilated cardiomyopathy; the female sex was associated with systemic diseases, valvular heart disease, and diabetes. The incidence of CHF requiring hospitalization per 100,000 in the population was 1.2 to 263 men and 1.1 to 129 women, in the youngest (age 16 to 30 years) and oldest (61 to 65 years) age groups, respectively. The 5-year survival rate was 50%. Analysis of causes performed with Cox's proportional hazards model for survival showed that age, IHD, alcohol, and diabetes were independent and powerful predictors of mortality (p < 0.001). The mode of death was progressive heart failure in 54% and sudden death in 26%. We concluded that the prognosis in patients with CHF was still very poor, even among this young population. The most common cause of CHF was IHD, and the second was hypertension.

Entities:  

Mesh:

Year:  1993        PMID: 8362719     DOI: 10.1016/0002-8703(93)90414-5

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  14 in total

1.  [Cost effectiveness of bisoprolol in heart failure. Economic evaluation of the Cardiac Insufficiency Bisoprolol Study (CIBIS) for Germany].

Authors:  P K Schädlich; B Paschen; J G Brecht
Journal:  Med Klin (Munich)       Date:  1997-08-15

2.  Epidemiological burden of heart failure.

Authors:  L Tavazzi
Journal:  Heart       Date:  1998-06       Impact factor: 5.994

Review 3.  Cardiogenic diabetes.

Authors:  Maya Guglin; Arnaldo Villafranca; Anthony Morrison
Journal:  Heart Fail Rev       Date:  2014-09       Impact factor: 4.214

Review 4.  Hypertension, hypertrophy, heart failure.

Authors:  M G Nicholls
Journal:  Heart       Date:  1996-11       Impact factor: 5.994

Review 5.  The pharmacoeconomics of ACE inhibitors in chronic heart failure.

Authors:  J McMurray; A Davie
Journal:  Pharmacoeconomics       Date:  1996-03       Impact factor: 4.981

Review 6.  Advanced heart failure and transplantation in women.

Authors:  Mary Norine Walsh
Journal:  Curr Cardiol Rep       Date:  2005-05       Impact factor: 2.931

Review 7.  Current status of the epidemiology of heart failure.

Authors:  W B Kannel
Journal:  Curr Cardiol Rep       Date:  1999-05       Impact factor: 2.931

8.  Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.

Authors:  P K Schädlich; E Huppertz; J G Brecht
Journal:  Pharmacoeconomics       Date:  1998-12       Impact factor: 4.981

Review 9.  Sex-related differences in patients' responses to heart failure therapy.

Authors:  Alon Barsheshet; Andrew Brenyo; Ilan Goldenberg; Arthur J Moss
Journal:  Nat Rev Cardiol       Date:  2012-02-14       Impact factor: 32.419

10.  Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute.

Authors:  Douglas S Lee; Philimon Gona; Ramachandran S Vasan; Martin G Larson; Emelia J Benjamin; Thomas J Wang; Jack V Tu; Daniel Levy
Journal:  Circulation       Date:  2009-06-08       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.